A new randomized clinical trial has revealed that just 24 minutes of listening to specially designed music paired with ...

The development of robust clinical trial methodologies increasingly relies on advanced statistical frameworks for model selection and the characterisation of dose–response relationships. With modern ...

Onvansertib in combination with both chemo/bev regimens was well-tolerated. There were no major or unexpected toxicities observed and no additive adverse events. Grade 3 or higher adverse events were ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553-221, of its chikungunya vaccine, Ixchiq, in 304 healthy paediatric ...

Although the correlate of protection is unknown, the findings show that standard doses should be used in infants.

A new study published in the journal of The Lancet Infectious Diseases showed that over a 100,000-fold dosage range, a single ...

The Phase 2b study demonstrated a statistically significant dose-response relationship at the primary endpoint following a single administration of MM120 across four dose levels, with improvements ...

CytoAgents Inc. completed the dose-limiting toxicity observation for the first cohort in a trial targeting CRS in blood cancer patients. The Safety Review Committee approved dose escalation for the ...

Hepatic steatosis is a core pathological feature of metabolic dysfunction-associated steatotic liver disease (MASLD). It not ...

Please provide your email address to receive an email when new articles are posted on . Patients with ankylosing spondylitis who had an inadequate response to secukinumab at 16 weeks saw no benefit at ...